-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on BridgeBio Oncology, Raises Price Target to $29

Benzinga·03/06/2026 12:13:22
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and raises the price target from $27 to $29.